Pharming Group (NASDAQ:PHAR) Shares Up 6.2% – Still a Buy?

Shares of Pharming Group (NASDAQ:PHAR) rose 6.2% during trading on Monday . The stock traded as high as $9.65 and last traded at $9.41. Approximately 2,319 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 5,913 shares. The stock had previously closed at $8.86.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PHAR. Oppenheimer dropped their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. HC Wainwright reissued a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th. Finally, Jefferies Financial Group initiated coverage on Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

Pharming Group Trading Up 3.5 %

The business’s fifty day moving average price is $9.34 and its 200 day moving average price is $8.50. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $623.84 million, a PE ratio of -35.27 and a beta of -0.10.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.